Physician profile
Samuel Rammage
NPI 1386363489
$4,927.82
in general payments reported to CMS, 2019-2025
20 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $171 · 2023: $1,716 · 2024: $1,706 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,726 · Education: $31.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,725.50 |
| Education | $31.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,276.42 | 2022-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Ultreon |
| Astrazeneca Pharmaceuticals LP | $403.63 | 2023-2024 | Brilinta, Farxiga |
| United Therapeutics Corporation | $294.47 | 2024-2025 | Tyvaso, Tyvaso |
| Impulse Dynamics (USA) INC. | $217.99 | 2023 | Optimizer |
| Abiomed | $215.60 | 2023-2025 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $192.95 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $168.17 | 2023-2025 | Verquvo, Winrevair |
| Novartis Pharmaceuticals Corporation | $162.41 | 2023-2025 | |
| Cvrx, INC. | $155.31 | 2025 | Barostim Neo System |
| Pfizer INC. | $151.62 | 2024-2025 | |
| Medtronic, INC. | $147.36 | 2024-2025 | Corevalve Evolut R |
| Amgen INC. | $110.06 | 2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.44 | 2023-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $96.90 | 2023-2024 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $87.25 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $50.91 | 2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $34.79 | 2023 | Inpefa |
| Vital Connect, INC | $22.41 | 2025 | Vitalpatch Rtm |
| Boston Scientific Corporation | $17.73 | 2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $17.40 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Rammage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.